BR112015016322A8 - formulações de liberação controlada de lorazepam - Google Patents

formulações de liberação controlada de lorazepam

Info

Publication number
BR112015016322A8
BR112015016322A8 BR112015016322A BR112015016322A BR112015016322A8 BR 112015016322 A8 BR112015016322 A8 BR 112015016322A8 BR 112015016322 A BR112015016322 A BR 112015016322A BR 112015016322 A BR112015016322 A BR 112015016322A BR 112015016322 A8 BR112015016322 A8 BR 112015016322A8
Authority
BR
Brazil
Prior art keywords
release
lorazepam
controlled release
release formulations
controlled
Prior art date
Application number
BR112015016322A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112015016322A2 (pt
Inventor
A Saltel Douglas
Vachon Michael
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015016322(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of BR112015016322A2 publication Critical patent/BR112015016322A2/pt
Publication of BR112015016322A8 publication Critical patent/BR112015016322A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112015016322A 2013-01-09 2014-01-09 formulações de liberação controlada de lorazepam BR112015016322A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08
PCT/US2014/010863 WO2014110248A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Publications (2)

Publication Number Publication Date
BR112015016322A2 BR112015016322A2 (pt) 2017-07-11
BR112015016322A8 true BR112015016322A8 (pt) 2018-01-23

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015016322A BR112015016322A8 (pt) 2013-01-09 2014-01-09 formulações de liberação controlada de lorazepam

Country Status (16)

Country Link
EP (1) EP2943186A1 (ko)
JP (1) JP2016504391A (ko)
KR (1) KR20150127037A (ko)
CN (1) CN105188682A (ko)
AU (1) AU2014205356A1 (ko)
BR (1) BR112015016322A8 (ko)
CA (1) CA2897313A1 (ko)
CL (1) CL2015001921A1 (ko)
HK (1) HK1213803A1 (ko)
IL (1) IL239778A0 (ko)
MX (1) MX2015008757A (ko)
PE (1) PE20151431A1 (ko)
PH (1) PH12015501533A1 (ko)
RU (1) RU2015128914A (ko)
SG (1) SG11201505352RA (ko)
WO (1) WO2014110248A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008756A2 (pt) 2017-11-01 2020-10-13 Edgemont Pharmaceuticals, LLC Trust composições farmacêuticas orais de lorazepam resistentes a álcool

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (ko) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
JPS61501511A (ja) * 1984-03-21 1986-07-24 アメリカン・ホ−ム・プロダクツ・コ−ポレイション 徐放性医薬カプセル
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
AU2141202A (en) 2000-12-05 2002-06-18 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
KR100822519B1 (ko) * 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제

Also Published As

Publication number Publication date
CL2015001921A1 (es) 2015-12-18
BR112015016322A2 (pt) 2017-07-11
AU2014205356A1 (en) 2015-07-30
JP2016504391A (ja) 2016-02-12
KR20150127037A (ko) 2015-11-16
PE20151431A1 (es) 2015-09-23
PH12015501533A1 (en) 2015-10-05
CN105188682A (zh) 2015-12-23
MX2015008757A (es) 2016-02-05
HK1213803A1 (zh) 2016-07-15
CA2897313A1 (en) 2014-07-17
IL239778A0 (en) 2015-08-31
SG11201505352RA (en) 2015-08-28
RU2015128914A (ru) 2017-02-14
EP2943186A1 (en) 2015-11-18
WO2014110248A1 (en) 2014-07-17

Similar Documents

Publication Publication Date Title
BR112018010018A2 (pt) moduladores de ror-gama
MX2020012310A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
AR081774A1 (es) Composiciones farmaceuticas de co-cristales de tramadol y coxibs
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
MX2015008286A (es) Composiciones multipolimericas para liberación transdermica de farmaco.
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
BR112013010829A2 (pt) composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma
MX369742B (es) Formulación de liberación modificada.
CY1123933T1 (el) Σκευασματα παρατεταμενης αποδεσμευσης λοραζεπαμης
TR201902755T4 (tr) Depolama kararliliğina sahi̇p li̇yofi̇li̇ze tri̇pepti̇t formülasyonlari.
UY31805A (es) Agonistas m1, composiciones farmacéuticas de los mismos, procesos para su preparacion y sus usos para el tratamiento del dolor
BR112015016322A2 (pt) formulações de lorazepam de liberação controlada
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
UY34080A (es) Composición farmacéutica para administración oral que comprende fexofenadina y métodos de preparación
RU2012139394A (ru) Комбинированный гемостатический препарат для наружного применения
ECSP16005208A (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
EA201590732A1 (ru) Диспергируемая таблетка
NZ702849A (en) Genotype- or phenotype-based drug formulation
ECSP15005163A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
CR20150411A (es) Composiciones farmacéuticas que contienen dexketoprofeno y tramadol
AR094391A1 (es) Formulaciones de lorazepam de liberación sostenida
IN2013MU02110A (ko)
IN2013MU02111A (ko)
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2496 DE 06/11/2018.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI